The extensive use of beta-lactam antibiotics has created major resistance problems leading to increased morbidity, mortality and health-care costs. Resistance is most often mediated by beta-lactamases (BLs), which have emerged in both Gram-positive and Gram-negative bacteria [1,2]. Medicinal chemists have introduced beta-lactam-based molecules that inhibit or are stable to their action. These molecules are themselves beta-lactams, making it easier for bacteria to respond by adapting previously evolved mechanisms. Many bacteria are now resistant to these anti-resistance compounds. Thus there is a growing need for new broad-spectrum beta-lactamases inhibitors in general and especially against Metallo BLs (MBLs)[3,4]. Their substrate promiscuity, their resistance to available drugs, the easiness of variants appearance and transferability make MBLs the most worrisome BLs . Focusing on the de novo, non beta-lactam like derivatives we identified, through a structure-based in silico screening of commercially available library using FLAP, several promising candidates active against class B beta-lactamases (MBL). The binding affinities of the high scoring hits were measured in vitro revealing, for some of them, low micromolar affinity towards BLs. To investigate the potential of these compounds to reverse antibiotic resistance, we are undertaking antimicrobial activity studies in bacterial cell culture. The ability of novel compounds to synergize antibiotics against pathogenic resistant bacteria, as well as their ability to evade those mechanisms normally involved in resistance to beta-lactam-based inhibitors are now under evaluation. Moreover, since our inhibitors are novel, non beta-lactam based, we expect them to do not up-regulate beta-lactamase expression in cell culture. X-ray crystallography studies are now in progress to confirm our docking prediction and to deeply investigate the structural requirement necessary for proficuous hit to lead generation.
|Data di pubblicazione:||2016|
|Titolo:||Designing novel inhibitors for Metallo beta-lactamases.|
|Nome del convegno:||ICAR2016. IV International Conference on Antimicrobial Research.|
|Luogo del convegno:||Torremolinos-Malaga (Spain),|
|Data del convegno:||29 June - 1 July 2016.|
|Citazione:||Designing novel inhibitors for Metallo beta-lactamases / Tondi, Donatella. - (2016). ((Intervento presentato al convegno ICAR2016. IV International Conference on Antimicrobial Research. tenutosi a Torremolinos-Malaga (Spain), nel 29 June - 1 July 2016..|
|Tipologia||Relazione in Atti di Convegno|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris